Abstract
Recently, a new immunometric assay (Cyfra 21-1) was developed to measure serum concentrations of a soluble fragment of cytokeratin subunit 19. With this method, supplied by Boehringer Mannheim (EIA Test Cyfra 21-1), an Italian multicenter trial was performed in patients with lung cancer. Cyfra 21-1 serum levels were determined in 568 normal subjects (blood donors), 607 patients with non-malignant diseases (491 respiratory diseases) and 730 patients with malignancies. In the latter group 584 had lung cancer. All these 584 patients had pathologically confirmed disease; 314 were epidermoid tumors, 166 adenocarcinomas, 88 small cell cancers and 16 large cell cancers. In the 568 healthy blood donors the mean Cyfra 21-1 value was 0.91 ng/ml (SD 0.47 ng/ml; range 0.05-2.90 ng/ml). A threshold of 1.9 ng/ml was chosen as the upper limit of normality. High levels of Cyfra 21-1 were observed in patients with chronic hepatitis (positivity rate: 17/51-33.3%) and with pancreatitis (positivity rate 5/16-31.3%). In 114 out of 491 (23.2%) patients with respiratory diseases Cyfra 21-1 showed values greater than 1.9 ng/ml. The overall sensitivity (all stages) of Cyfra 21-1 in lung cancer was 65.6% (383/584). When the histology was considered the highest positivity rates were found in patients with sguamous cell tumors (226/314; 72%) followed by adenocarcinomas (105/166; 63%). In patients with SCLC the global sensitivity was 52.3% (46/88). Higher sensitivity of Cyfra 21-1 was observed from stage I to stage IV (53.9% vs 85.7%; Chi square: p <0.01). When comparing patients in whom curative resections were possible (up to stage IIIa) with patients suffering from inoperable tumors, a significant difference in Cyfra 21-1 positivies was found (59% vs 81.5%; Chi square p <0.01).
| Original language | English |
|---|---|
| Pages (from-to) | 89-95 |
| Number of pages | 7 |
| Journal | International Journal of Biological Markers |
| Volume | 9 |
| Issue number | 2 |
| Publication status | Published - 1994 |
Fingerprint
Keywords
- Cyfra 21-1
- cytokeratins
- lung cancer
- tumor markers
ASJC Scopus subject areas
- Immunology
- Biochemistry
Cite this
Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer : Results of a multicenter trial. / Bombardieri, E.; Seregni, E.; Bogni, A.; Ardit, S.; Belloli, S.; Busetto, A.; Caniello, B.; Castelli, M.; Cianetti, A.; Correale, M.; De Angelis, G.; Gandolfo, G. M.; gion, M.; Macchia, V.; Mione, R.; Navaglia, F.; Onetto, M.; Paganbuzzi, M.; Pecchio, F.
In: International Journal of Biological Markers, Vol. 9, No. 2, 1994, p. 89-95.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer
T2 - Results of a multicenter trial
AU - Bombardieri, E.
AU - Seregni, E.
AU - Bogni, A.
AU - Ardit, S.
AU - Belloli, S.
AU - Busetto, A.
AU - Caniello, B.
AU - Castelli, M.
AU - Cianetti, A.
AU - Correale, M.
AU - De Angelis, G.
AU - Gandolfo, G. M.
AU - gion, M.
AU - Macchia, V.
AU - Mione, R.
AU - Navaglia, F.
AU - Onetto, M.
AU - Paganbuzzi, M.
AU - Pecchio, F.
PY - 1994
Y1 - 1994
N2 - Recently, a new immunometric assay (Cyfra 21-1) was developed to measure serum concentrations of a soluble fragment of cytokeratin subunit 19. With this method, supplied by Boehringer Mannheim (EIA Test Cyfra 21-1), an Italian multicenter trial was performed in patients with lung cancer. Cyfra 21-1 serum levels were determined in 568 normal subjects (blood donors), 607 patients with non-malignant diseases (491 respiratory diseases) and 730 patients with malignancies. In the latter group 584 had lung cancer. All these 584 patients had pathologically confirmed disease; 314 were epidermoid tumors, 166 adenocarcinomas, 88 small cell cancers and 16 large cell cancers. In the 568 healthy blood donors the mean Cyfra 21-1 value was 0.91 ng/ml (SD 0.47 ng/ml; range 0.05-2.90 ng/ml). A threshold of 1.9 ng/ml was chosen as the upper limit of normality. High levels of Cyfra 21-1 were observed in patients with chronic hepatitis (positivity rate: 17/51-33.3%) and with pancreatitis (positivity rate 5/16-31.3%). In 114 out of 491 (23.2%) patients with respiratory diseases Cyfra 21-1 showed values greater than 1.9 ng/ml. The overall sensitivity (all stages) of Cyfra 21-1 in lung cancer was 65.6% (383/584). When the histology was considered the highest positivity rates were found in patients with sguamous cell tumors (226/314; 72%) followed by adenocarcinomas (105/166; 63%). In patients with SCLC the global sensitivity was 52.3% (46/88). Higher sensitivity of Cyfra 21-1 was observed from stage I to stage IV (53.9% vs 85.7%; Chi square: p <0.01). When comparing patients in whom curative resections were possible (up to stage IIIa) with patients suffering from inoperable tumors, a significant difference in Cyfra 21-1 positivies was found (59% vs 81.5%; Chi square p <0.01).
AB - Recently, a new immunometric assay (Cyfra 21-1) was developed to measure serum concentrations of a soluble fragment of cytokeratin subunit 19. With this method, supplied by Boehringer Mannheim (EIA Test Cyfra 21-1), an Italian multicenter trial was performed in patients with lung cancer. Cyfra 21-1 serum levels were determined in 568 normal subjects (blood donors), 607 patients with non-malignant diseases (491 respiratory diseases) and 730 patients with malignancies. In the latter group 584 had lung cancer. All these 584 patients had pathologically confirmed disease; 314 were epidermoid tumors, 166 adenocarcinomas, 88 small cell cancers and 16 large cell cancers. In the 568 healthy blood donors the mean Cyfra 21-1 value was 0.91 ng/ml (SD 0.47 ng/ml; range 0.05-2.90 ng/ml). A threshold of 1.9 ng/ml was chosen as the upper limit of normality. High levels of Cyfra 21-1 were observed in patients with chronic hepatitis (positivity rate: 17/51-33.3%) and with pancreatitis (positivity rate 5/16-31.3%). In 114 out of 491 (23.2%) patients with respiratory diseases Cyfra 21-1 showed values greater than 1.9 ng/ml. The overall sensitivity (all stages) of Cyfra 21-1 in lung cancer was 65.6% (383/584). When the histology was considered the highest positivity rates were found in patients with sguamous cell tumors (226/314; 72%) followed by adenocarcinomas (105/166; 63%). In patients with SCLC the global sensitivity was 52.3% (46/88). Higher sensitivity of Cyfra 21-1 was observed from stage I to stage IV (53.9% vs 85.7%; Chi square: p <0.01). When comparing patients in whom curative resections were possible (up to stage IIIa) with patients suffering from inoperable tumors, a significant difference in Cyfra 21-1 positivies was found (59% vs 81.5%; Chi square p <0.01).
KW - Cyfra 21-1
KW - cytokeratins
KW - lung cancer
KW - tumor markers
UR - http://www.scopus.com/inward/record.url?scp=0028305555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028305555&partnerID=8YFLogxK
M3 - Article
C2 - 7523547
AN - SCOPUS:0028305555
VL - 9
SP - 89
EP - 95
JO - International Journal of Biological Markers
JF - International Journal of Biological Markers
SN - 0393-6155
IS - 2
ER -